Kazia Raises $40M in Financing to Expand Paxalisib Trials
Kazia Therapeutics (NASDAQ: KZIA) has raised approximately $40 million through a registered public offering, which was described as oversubscribed. The financing includes the issuance of American Depositary Shares and warrants that could potentially generate an additional $80 million if fully exercised. Kazia plans to use these funds primarily for advancing paxalisib trials in various cancers including triple-negative breast cancer, HR-positive HER2-negative metastatic breast cancer, and proficient mismatch repair colorectal cancer. The company has also expanded its ongoing breast-cancer study into pretreated HR-positive, HER2-negative metastatic disease. The trial will assess the safety and tolerability of paxalisib in combination with other therapies compared to a control arm using fulvestrant alone. While preclinical results show promise, including tumor-volume reductions and resensitization effects, clinical evidence remains limited at this stage. The financing provides Kazia with more flexibility but also introduces potential dilution risks due to the large number of warrants issued.
Tickers: $KZIA
Topics: biotech clinical trials financing